Onc Now: Episode 27: What's Next in Genitourinary Cancer Care?

EMJ Podcast: Insights For Healthcare Professionals

In this episode, Viktor Grünwald shares his journey through a remarkable career in oncology, his focus on urogenital cancers, and his hopes for the future of cancer treatment. From reflections on research to European Society for Medical Oncology (ESMO) 2025 predictions and the promise of precision medicine, Grünwald offers an insightful look at evolving therapies and the pursuit of higher cure rates.

Timestamps:

00:00 – Introduction

01:03 – Reflections on his career

02:06 – Balancing research, clinical duties, and teaching

03:10 – Specialising in urogenital cancers

04:50 – Viktor's hobbies and interests

05:47 – Current landscape of genitourinary cancers

09:09 – Treatment modalities

11:09 – The CLEAR study

12:54 – European Society for Medical Oncology (ESMO) 2025 predictions

15:57 – The potential of precision medicine

19:09 – Viktor's three wishes for healthcare

Disclosure: Grünwald has received honoraria from Bristol Myers Squibb, Ipsen, Eisai, MSD Oncology, Merck Serono, AstraZeneca, Advanced Accelerator Applications (acquired by Novartis), Astellas Pharma, Amgen, Johnson & Johnson/Janssen, Telix Pharmaceuticals, Gilead Sciences, and Roche; research funding from Amgen, MSD Oncology, Bristol Myers Squibb, Seattle Genetics (now Seagen; acquired by Pfizer), Ipsen, Gilead Sciences, Bicycle Therapeutics, Exelixis, Novartis, Roche, and Johnson & Johnson/Janssen, with payment to the institution; travel/accommodation/expenses from Pfizer, Janssen, Merck Serono, Ipsen, and Amgen; and held consulting or advisory roles for Bristol Myers Squibb, Pfizer, Novartis, MSD Oncology, Ipsen, Janssen-Cilag, Eisai, Debiopharm, Gilead Sciences, Oncorena, Synthekine, and Recordati.

The CLEAR study was sponsored Eisai and Merck Sharp & Dohmre.